Scientists probe gene link to rare brain disease after infections
NCT ID NCT06731790
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how a specific gene mutation (RANBP2) affects the immune system in people with Acute Necrotizing Encephalopathy type 1 (ANE1), a rare brain condition triggered by infections. Researchers compared blood samples from 35 participants, including patients with the mutation and healthy controls, to measure inflammatory markers. The goal is to better understand why some people develop severe brain inflammation, which could guide future research into treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could reveal why some people with a RANBP2 mutation develop severe brain inflammation after common infections, pointing toward future treatments.
What could go wrong
This is a small, early-stage study with only 35 participants, focused on understanding the disease rather than testing a treatment. Results may not apply to all patients or lead directly to therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RARE GENETIC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Gui de Chauliac
Montpellier, Hérault, 34295, France